Status:
RECRUITING
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Lead Sponsor:
Eli Lilly and Company
Conditions:
Atherosclerosis Cardiovascular Disease
Chronic Kidney Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney diseas...
Eligibility Criteria
Inclusion
- Have established ASCVD and/or CKD
Exclusion
- Have type 1 diabetes
- Have had a major heart condition within 60 days prior to screening
- Have New York Heart Association Functional Classification Class IV heart failure
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2031
Estimated Enrollment :
7140 Patients enrolled
Trial Details
Trial ID
NCT07241390
Start Date
December 1 2025
End Date
August 1 2031
Last Update
March 6 2026
Active Locations (565)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de Investigaciones Clínicas Bahia Blanca
Bahía Blanca, Argentina, 8000
2
CONEXA Investigacion Clinica S.A.
Buenos Aires, Argentina, 1012
3
Buenos Aires Macula S.A
Buenos Aires, Argentina, 1061
4
CIPREC
Buenos Aires, Argentina, 1061